Reduced serum levels of anti-Mullerian hormone is a putative biomarker of early knee osteoarthritis in middle-aged females at menopausal transition

Eiji Sasaki1*, Daisuke Chiba1, Seiya Ota1, Yuka Kimura3, Shizuka Sasaki1, Yuji Yamamoto3, Maika Oishi2, Kaori Iino2, Masataka Ando3, Eiichi Tsuda4 & Yasuyuki Ishibashi1

A recent epidemiological study revealed that the highest prevalence of early knee osteoarthritis (OA) was observed in females aged ≥ 50 years. The major causal factor of early knee OA was sex. Despite the relevance of estrogen in evaluating chondral and bone metabolism in OA, it is not easily clinically monitored because irregular menstrual cycles induce unstable female hormone patterns during menopausal transitions. Anti-Mullerian hormone (AMH) has been found to be a new stable biomarker to predict menopause. This study aimed to investigate the association between menopausal transition and early knee OA by using serum biomarkers, with special focus on AMH. A total of 518 female volunteers who participated in the Iwaki cohort study were enrolled and divided into pre-menopause and post-menopause groups. Weight-bearing anterior–posterior knee radiographs were classified by Kellgren–Lawrence (KL) grade, and grade ≥ 2 was defined as radiographic knee OA. In participants with KL grades 0 and 1, early knee OA was defined by Luyten’s criteria. AMH, luteinizing hormone, follicle-stimulating hormone, estradiol (pg/ml), prolactin, and testosterone were measured on the female hormones. Bone mineral density at a distal radius was measured. The predictive power of female hormones for early knee OA was estimated by ROC analysis (comparison of area under curve, AUC) and regression analysis. Fifty-two participants (10.0%) were diagnosed with early knee OA and 204 (39.4%) with radiographic knee OA. In 393 (75.9%) females, menopause began. From the ROC analysis in pre-menopausal females, cutoff value of AMH for detecting early knee OA was 0.08 ng/ml (area under curve (AUC), 0.712; 95% CI, 0.527–0.897; p value, 0.025; odds ratio, 8.28). AUCs of other female hormones did not reach the level of AMH (range, 0.513 of prolactine to 0.636 of estradiol). Logistic regression analysis focusing on AMH reduction at menopausal transition showed that the related AMH below 0.08 ng/ml was significantly related to the presence of early knee OA (p = 0.035; odds ratio, 5.55). Reduced serum levels of AMH in middle-aged females were correlated with the presence of early knee OA, which might be a useful serum biomarker.

1Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan. 2Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. 3Department of Social Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. 4Department of Rehabilitation Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. *email: e_sasaki@hirosaki-u.ac.jp
after menopause is known to cause a reduction in bone mineral density (BMD)\(^1\) and suppress cartilage and subchondral bone remodeling\(^1\). However, despite the relevance of estrogen in evaluating chondral and bone metabolism, few reports exist to investigate the relationship between decreasing female hormones and early knee OA, whereas both conditions are observed among females \(\geq 50\) years old. One of the reasons is that the female hormones are not easily clinically monitored because they are in menopausal transitions. Menopausal transition is pre-menopausal condition and encompasses a period of dynamic changes in reproductive and nonreproductive tissues, which causes irregular menstrual cycles in middle-aged females\(^1\). Thus, it is difficult to fully understand the relationship between dysfunction of female hormones and early knee OA. In contrast, recently, anti-Mullerian hormone (AMH) has been found to be a new stable biomarker to predict menopause. AMH is a glycoprotein dimer, only expressed in growing follicles, and has been identified as a marker of ovarian aging\(^1\). Moreover, serum levels of AMH decreases during menopausal transition, as previous reports found that the serum levels of AMH reduces 3 years before menopause\(^2\). Another advantage of AMH is that it is not affected by menstrual cycles like estradiol, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Hence, the serum levels of AMH are beneficial in understanding the association of follicle activity during the early phase of knee OA.

This epidemiological study aimed to investigate the association between menopausal transition and early knee OA by using several serum biomarkers, with special focus on AMH. Furthermore, the influence of bone fragility related to menopause on knee OA was investigated. We hypothesized that reduced serum levels of AMH could sensitively reflect the presence of early knee OA. Furthermore, progressed stage of knee OA would be associated with menopause and bone fragility regardless of serum levels of AMH.

**Methods**

The participants were volunteers for the Iwaki Health Promotion Project, which is a community-based preventive medicine program that aims at improving average life expectancy by performing general health check-ups\(^5\). The participants were recruited using mass media advertisements and with the help of public health nurses. All participants provided written informed consent, and the study was done in agreement with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards and conducted with the approval of the ethics committee of Hirosaki University Graduate School of Medicine (2016-028).

**Participants.** Out of the 12,000 eligible residents, 1148 volunteers were enrolled in this study (Fig. 1). The exclusion criteria of this study were as follows: male sex (n = 455), patients under treatment of rheumatoid arthritis or with anti-cyclic citrullinated peptide antibody of more than 4.5 U/ml (n = 26), postoperative patients with total knee arthroplasty and arthrodesis (n = 9), and incomplete data (n = 20). After the first exclusion, a total of 648 female participants were included, and their distribution of estradiol (Fig. 2A) and AMH (Fig. 2B) per their ages were shown in a scatter plot. Data of females aged 40 years and above were considered for further statistical analysis. All the participants answered self-reported questionnaires about menstrual condition, and the menopause was defined as the time when there has been no menstrual periods for 12 consecutive months. Additional questionnaires concerning lifestyle habits, including routine alcohol consumption, cigarette smoking, and fitness habits, were administered. The presence of these habits was defined as routine drinking 1 or more days a week regardless of the amount of alcohol, smoking more than a cigarette every day, or performing exercise \(\geq 2\) days per week regardless of fitness type and length. Former habits and chance drinking were not included for lifestyle habits. These habits were included as categorical variables (yes/no) in the statistical analysis. For the anthropometric evaluation, height and weight were measured and recorded and body mass index (BMI) was calculated.

**Blood examination.** Blood samples were taken from all participants before breakfast after a period of 10 or more hours without food. Blood analysis were performed by the LSI Medience Corporation (LSI Medience Corp., Tokyo, Japan). This company has an ISO-15189-accredited laboratory, and serum assays were performed under strict conditions. AMH (ng/ml, CLEIA), LH (mIU/ml, CLIA), FSH (mIU/ml, CLIA), estradiol (pg/
ml, CLIA), prolactin (ng/ml, CLIA), and testosterone (ng/ml, CLIA) were measured on the female hormones. Further, bone metabolism was evaluated by the following markers: type I procollagen N-terminal propeptide total (total PINP, μg/l, ECLIA), bone alkaline phosphatase (BAP, μg/l, CLEIA), N-terminal telopeptide (NTx, nMBCE/l, EIA), and tartrate-resistant acid phosphatase 5b (TRACP-5b, mU/dl, EIA). Furthermore, pentosidine (pmol/ml, HPLC) and homocysteine (nmol/ml, LC–MS/MS) were measured for bone quality. The inflammation markers hyaluronan (ng/ml, LA), matrix metalloproteinase-3 (MMP-3, ng/ml, LA), high sensitivity C-reactive protein (hs-CRP, mg/dl, Nephelometry), adiponectin (μg/ml, LA), leptin (ng/ml, RIA), and interleukin-6 (IL-6, pg/ml, CLEIA) were examined.

Radiographic evaluation. A radiographic examination of the knee was performed using a digital radiographic device (CXDI-40EG, Canon Inc. Tokyo, Japan). Experienced radiologists and orthopedic surgeons obtained the weight-bearing, full extension, and anterior–posterior radiographs of both knees with foot map positioning on the day of the check-up. The beam was positioned parallel to the floor and aimed at the joint space, and the sequencing was set at 60 kV, 50 mAs, and 80 ms for all participants. The images were converted into JPEG format files. OA severity in each knee was classified as KL grade 0 to 4 using the KL radiographic atlas by two trained orthopedic surgeons (DC and SO)23. The interclass correlation coefficient from the two surgeons was 0.815. These surgeons were blinded to the sequence in which the radiographs were acquired and the clinical status of the participants. In this study, KL grades 0 and 1 were classified into pre-radiographic OA stage, non-OA, and early knee OA. Participants with KL grades 2, 3, or 4 in the most affected knees were diagnosed with radiographic knee OA.

Classification criteria for early OA of the knee. Early knee OA was defined based on the classification criteria proposed by Luyten4. The classification criteria for early knee OA were as follows: A) patient-based questionnaires, the knee injury and osteoarthritis outcome scores (KOOS)24 (two of the following needed to score “positive” (i.e., ≤ 85%): pain (9 items), symptoms (7 items), activities of daily living (ADL) (short version, 7 items), and knee-related quality of life (QOL) (4 items)); B) clinical examination (at least one of the following needed to present: joint line tenderness or crepitus of the knee); C) radiographs, KL grade zero and one at the standing, extension, and weight-bearing positions. Based on the above criteria, subjects with KL grade 0/1 were classified into non-OA and early knee OA.

Bone mineral density measurements. The BMD of the forearm was determined by dual-energy X-ray absorptiometry using DCS-600EXV (Hitachi Aloka Medical, Tokyo, Japan) based on a previous report25. Briefly, the region of interest of the BMD was measured on the non-dominant side, one third of the distal radius, unless there was a history of previous fracture, where the dominant side was measured.

Statistical analysis. Demographic data among non-OA, early knee OA, and radiographic knee OA groups were shown as mean ± standard deviations. Chi-square test for categorical variables and analysis of variance (ANOVA) and Tukey test for continuous variables were performed to compare the three groups’ demographic data. To estimate the odds ratio of radiographic knee OA by menopause, crude logistic regression analysis was performed, with radiographic knee OA as a dependent variable and menopause as an independent variable. To estimate cutoff values of female hormones for early knee OA among pre-menopausal females, receiver operating characteristic (ROC) analysis was performed. The plot of false-positive fraction and true-positive fraction build curve and area under the curve (AUC) was calculated. The cutoff point was defined from the nearest point to the true positive. Based on the cutoff value of AMH and menopausal condition, the prevalence of early knee OA
and radiographic knee OA were estimated. Furthermore, the Spearman’s correlation coefficients were calculated using female hormones, bone metabolic markers, and inflammation markers. Finally, to investigate the correlation among menopause, AMH, early knee OA, and radiographic knee OA, logistic regression analyses using a backward stepwise selection method were performed, with the early knee OA or radiographic knee OA as a dependent variable and BMI, BMD, bone metabolic markers, and inflammation markers as basal independent variables. In addition to basal independent variables, regression model 1 was set to investigate the risk of lower AMH on early knee OA in pre-menopausal females with KL grade 0 and 1. In this analysis, categorized AMH (pre-menopause with AMH ≥ 0.08, pre-menopause with AMH < 0.08, or post-menopause) was used as an independent variable. Subsequently, the same independent variables were used in regression model 2 to investigate the risk of radiographic knee OA. Regression model 3 included a categorized post-menopausal period of 5 years. Data input and analysis were performed using SPSS version 25.0 J (SPSS Inc., Chicago, IL, USA). A p value < 0.05 was considered statistically significant.

Ethics approval and consent to participate. All participants provided written informed consent, and the study was done in agreement with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards and conducted with the approval of the ethics committee of Hirosaki University Graduate School of Medicine (2016-028).

Consent for publication. Consent for publication were obtained from all of participants with consent to participate.

Results

Demographics of participants. Out of the 518 participants, 262 (50.6%) were classified as non-OA, 52 (10.0%) as early knee OA, and 204 (39.4%) as radiographic knee OA. There were no significant differences of age, BMI, and BMD between non-OA and early knee OA groups (Table 1). A total of 393 (75.9%) females were 49.4 ± 4.7 years old. The prevalence of OA in post-menopausal women was up to 48.1% and 12.0% in the pre-menopausal participants (p < 0.001). Regression analysis revealed that the odds ratio of radiographic knee OA by menopause was 6.79 (p < 0.001; 95% CI, 3.82–12.07).

Association between early knee OA and females hormones. Correlation between age and estradiol was weak (r = −0.281, p = 0.002) at the pre-menopausal stage, and there was no correlation post-menopause (r = 0.334) (Fig. 2A). In contrast, the values of AMH in pre-menopausal females were 0.93 ± 1.22 ng/ml, which was highly correlated with age (r = −0.738; p < 0.001); the levels in post-menopausal females were 0.02 ± 0.01 ng/ml regardless of age (p = 0.126) (Fig. 2B). Furthermore, the values of estradiol and AMH of early knee OA and radiographic knee OA were significantly lower than that of the non-OA group (Table 1). ROC analysis in pre-menopausal females with KL grade 0 and 1 showed that reduced serum levels of AMH reflected the presence of early knee OA, and its cutoff value was estimated at 0.08 ng/ml. Additionally, the odds ratio of AMH < 0.08 ng/ml from ROC analysis. In addition, reduced serum levels of both AMH and estradiol, which were proof of menopause, were correlated with lower BMD, higher turnover of bone metabolism, and increased inflammation. These results suggested that the decline of female hormone would track knee OA from the early stages.

Influence of bone metabolism on early knee OA and radiographic knee OA. Regarding bone fragility, the BMD of radiographic knee OA were lower than early knee OA and non-KOA (p < 0.001, respectively). Further, the values of BAP (p = 0.002), TRACP-5b (p = 0.002), and NTx (p < 0.001) of the radiographic knee OA group were significantly higher than those of the non-KOA group. Furthermore, the bone quality markers, pentosidine (p < 0.001), and homocysteine (p = 0.014) were worse in the radiographic knee OA group than in the non-KOA group. Bone metabolic and quality markers were negatively correlated with BMD, AMH, and estradiol concentration and positively correlated with LH and FSH (Table 4). A further comparison with inflammation markers showed that hyaluronan, MMP-3, leptin, and IL-6 concentrations in the radiographic knee OA group were higher than those in the non-KOA group. Hyaluronan moderately correlated with BMD (r = −0.516; p < 0.001), AMH (r = −0.443; p < 0.001), and estradiol (r = −0.388; p < 0.001) (Table 4).

Related factors for early knee OA and radiographic knee OA from regression analysis. Models 1 and 2 logistic regression analysis focusing on AMH reduction at menopausal transition showed that the related AMH below 0.08 ng/ml was significantly related to early knee OA (p = 0.035; odds ratio, 5.55) and radiographic knee OA (p = 0.032; odds ratio, 1.39). Model 3, analysis focusing on the post-menopausal period showed that the risk of radiographic knee OA increased by 1.24 times every 5 years post-menopause (p = 0.005) (Table 5).

Discussion

The most significant finding of this study was that reduced serum levels of AMH in middle-aged females were correlated with the presence of early knee OA. Furthermore, the cutoff value of serum AMH was estimated as 0.08 ng/ml from ROC analysis. In addition, reduced serum levels of both AMH and estradiol, which were proof of menopause, were correlated with lower BMD, higher turnover of bone metabolism, and increased inflammation. These results suggested that the decline of female hormone would track knee OA from the early stages.
The causation between AMH and early knee OA was not concluded from cross-sectional cohort study; however, current study proved an apparent association between AMH and early knee OA, which indicates AMH might be one of the biomarkers for early knee OA in association with decline in female hormone, bone fragility, and inflammation. Further longitudinal analysis are needed to reveal the prognostic power of AMH as a biomarker for early knee OA.

Females are at a higher risk of knee OA, and many several epidemiological studies revealed that the prevalence of OA in females were higher than in males. A systematic review estimated that the total odds ratio of females was 1.68 (95% CI, 1.37–2.07). Framingham study showed that the prevalence of OA in females was 36% and 1.2 times higher than that in males. In Japan, the prevalence of OA in females were 1.5–2.8 times higher than in males; the prevalence was higher than that of Caucasians. Considering the role played by menopause, a longitudinal study from Melbourne Women’s Midlife Health Project showed that those who have never undergone hormone therapy were at a higher risk of developing knee OA. Further, representative therapy decreased the incidence of knee OA. Although one systematic review concluded that there was no clear association between female hormonal aspects and knee OA, the relationship between radiographic knee OA and menopause shown in this study is supported by previous studies.

This study could reveal the application of AMH as a serum biomarker to reflect the presence of knee OA, especially at an early phase of the disease. Until now, it is known that female hormones influence the etiology of knee OA, its precise monitoring was challenging, especially in menopausal transition. In these situations, AMH, an ovarian aging marker, could reflect the presence of knee OA from the early phase. Although detailed direct mechanisms of AMH on knee OA have not revealed, ovarian aging led to the decrease of female hormones including estrogen. The longitudinal study would conclude the relationship among knee OA, menopause, and

| Table 1. Demographic data of non-KOA, early knee OA, and radiographic knee OA groups. Values are means ± standard deviation of the demographic data. Values in () indicate percentage in each group. Differences among the non-OA, early knee OA, and radiographic knee OA groups were compared by analysis of variance or chi-square test. A p value below 0.05 when compared with non-OA (*) and early knee OA (†) were considered statistically significant. KOOS The knee injury and osteoarthritis outcome scores, ADL Activities of daily livings, QOL Quality of life. |
|-----------------|-----------------|-----------------|
| Sample number  | Non-OA          | Early knee OA   | Radiographic knee OA |
| Age (y.o)      | 55.8 ± 10.5     | 58.8 ± 7.8      | 67.2 ± 9.8†          |
| Post-menopause (%) | 161 (61.5%)       | 43 (82.7%)      | 189 (92.6%) *          |
| Body mass index (kg/m²) | 22.0 ± 2.9     | 22.8 ± 3.5      | 23.8 ± 3.5*          |
| Bone mineral density (g/cm²) | 0.59 ± 0.10 | 0.58 ± 0.09      | 0.52 ± 0.09†          |
| KOOS pain      | 97.3 ± 6.0      | 75.4 ± 13.8*    | 79.5 ± 20.0*          |
| KOOS symptom   | 95.6 ± 5.6      | 78.7 ± 12.8*    | 80.2 ± 19.7*          |
| KOOD ADL short | 97.5 ± 7.0      | 79.2 ± 16.1*    | 80.2 ± 21.6*          |
| KOOS QOL       | 89.9 ± 14.3     | 58.2 ± 16.7*    | 63.2 ± 27.2*          |
| Anti-Mullerian hormone (ng/ml) | 0.39 ± 0.88 | 0.08 ± 0.31*       | 0.08 ± 0.46*          |
| Estradiol (pg/ml) | 50.9 ± 95.7      | 19.6 ± 50.8*    | 11.0 ± 21.0*          |
| Luteinizing hormone (mIU/ml) | 16.9 ± 11.2     | 19.6 ± 7.2      | 18.5 ± 9.2           |
| Follicle-stimulating hormone (mIU/ml) | 42.5 ± 29.8     | 53.9 ± 23.7*    | 50.9 ± 20.6*          |
| Prolactin (ng/ml) | 10.0 ± 9.2       | 10.6 ± 13.1     | 10.5 ± 16.2          |
| Testosterone (ng/ml) | 0.24 ± 0.09     | 0.24 ± 0.15     | 0.24 ± 0.09          |
| Type I procollagen N-terminal propeptide total (μg/l) | 49.2 ± 24.7     | 54.9 ± 20.6     | 52.6 ± 22.5          |
| Bone alkaline phosphatase (μg/l) | 13.4 ± 6.2      | 14.8 ± 4.6      | 15.6 ± 8.3*          |
| N-terminal teleopeptide (nMBCE/l) | 15.0 ± 4.6     | 16.9 ± 4.7      | 16.7 ± 6.5*          |
| Tartrate-Resistant Acid Phosphatase 5b (mU/dl) | 424.7 ± 194.6   | 508.8 ± 200.9*  | 509.7 ± 193.9*        |
| Pentosidine (pmol/ml) | 27.7 ± 11.9     | 30.4 ± 11.2     | 33.4 ± 16.3*          |
| Homocysteine (nmol/ml) | 8.2 ± 2.7       | 8.3 ± 1.9       | 9.0 ± 3.3*           |
| Hyaluronic acid (ng/ml) | 26.3 ± 29.7     | 30.7 ± 24.5     | 90.7 ± 262.6*         |
| Matrix metalloproteinase-3 (ng/ml) | 35.3 ± 14.3     | 39.7 ± 29.7     | 44.7 ± 34.5*         |
| High sensitivity C-reactive protein (mg/dl) | 0.06 ± 0.14     | 0.05 ± 0.14     | 0.09 ± 0.18          |
| Adiponectin (μg/ml) | 12.5 ± 6.0     | 12.1 ± 5.0      | 13.2 ± 6.1           |
| Leptin (ng/ml) | 10.0 ± 5.7      | 10.3 ± 5.8      | 12.2 ± 8.5*          |
| Interleukin-6 (pg/ml) | 1.3 ± 1.6       | 2.2 ± 6.1       | 1.9 ± 2.2*           |
| Fitness habit (%) | 58 (22.1%)      | 13 (25.0%)      | 48 (23.5%)           |
| Drinking habit (%) | 87 (33.3%)      | 13 (25.0%)      | 52 (25.6%)          |
| Smoking habit (%) | 64 (24.5%)      | 12 (23.1%)      | 30 (14.7%) *         |
AMH. Despite this limitation, AMH had an advantage that it is not affected by menstrual cycles like estradiol, LH, and FSH, would be isolated biomarker for early knee OA. Moreover, these results suggested that initiation of degenerative change was in line with the menopausal transition stage. In the early stages of knee OA, the Framingham study, including 710 knees with KL grade 0/1, showed the featured MRI findings in those with knee pain as having BMLs, attrition, and subchondral bone cysts. Further, the CHECK study, a 5-year longitudinal cohort of general population, showed that the incidence risk factors for knee OA from KL grade 0/1 were BMLs, effusion, and meniscal lesion on MRI. Bone abnormalities in the early stage of KL grade are likely to occur in the middle-aged female population. During menopausal transition, bone metabolism changes dramatically, corresponding to the intrinsic hormonal changes in females. Based on this evidence, the current data indicates that such abrupt menopausal transition reflects not only increased systemic bone metabolism but also focal bone abnormalities, which could induce osteoarthritic changes in knee joints.

In this regard, both osteoporosis and knee OA are attributed to menopause. However, the possibility of osteoporosis causing the development of knee OA is uncertain. Previous studies have reported that higher BMD is related to the incidence of knee OA. Conversely, from the basis of evidences in the most recent decade, Ota

Table 2. ROC analysis of female hormones for early knee osteoarthritis. ROC: AUC; area under the curve, 95% CI: 95% confidence interval, FPF False positive fraction, TPF True positive fraction.

| Female hormone                        | AUC     | 95% CI      | $\chi^2$ value | $p$ value | Cut-off value | FPF   | TPF   | Odds ratio |
|---------------------------------------|---------|-------------|----------------|-----------|---------------|-------|-------|------------|
| Anti-Mullerian hormone                | 0.712   | 0.527–0.897 | 5.05           | 0.025     | 0.08          | 0.30  | 0.78  | 8.28       |
| Estradiol                             | 0.636   | 0.399–0.873 | 1.27           | 0.260     | 20.00         | 0.15  | 0.56  | 7.17       |
| Luteinizing hormone                   | 0.677   | 0.487–0.866 | 3.33           | 0.068     | 10.27         | 0.28  | 0.78  | 9.13       |
| Follicle stimulating hormone          | 0.697   | 0.509–0.886 | 4.22           | 0.040     | 9.65          | 0.30  | 0.78  | 8.28       |
| Prolactin                             | 0.513   | 0.286–0.740 | 0.01           | 0.909     | 16.32         | 0.18  | 0.33  | 2.31       |
| Testosterone                          | 0.513   | 0.325–0.702 | 0.02           | 0.890     | 0.21          | 0.33  | 0.44  | 1.62       |

Table 3. Prevalence of knee osteoarthritis in menopausal transition and post-menopausal stage. Prevalence of early and radiographic knee osteoarthritis in menopausal transition and post-menopausal stage. In pre-menopausal stage, subjects were divided into two groups according to the cut-off value (0.08 ng/ml).

|                  | Pre-menopause | Post-menopause |
|------------------|---------------|---------------|
| AMH ≥ 0.08 (%)   | AMH < 0.08 (%)|               |
| Early knee OA    | 3.5 15.0      | 10.9          |
| Radiographic OA  | 12.9 48.1     |               |
et al. revealed that symptomatic BMLs on MRI were related to bone fragility, including lower BMD and high turnover of bone metabolism in middle-aged females without radiographic abnormalities. Furthermore, others reported a pathogenic mechanism since excessive bone resorption takes place in the early phase of OA. Previous reports support our results that lower BMD and increased bone metabolism of middle-aged females were correlated with the presence of knee OA. Indeed, osteoporotic osteoarthritis is reported as a particular type of OA and defined as OA showing a distinctive decrease in subchondral bone density accompanied by high remodeling rates. Further studies are needed to establish the relationship between bone fragility and knee OA at any phase.

Another interesting result in this study was that serum AMH concentration in the female population having knee OA was associated with serum inflammation markers. Systemic and focal inflammation in the synovium play an important role even in the early phase of knee OA. Previous reports support our results that lower BMD and increased bone metabolism of middle-aged females were correlated with the presence of knee OA. Indeed, osteoporotic osteoarthritis is reported as a particular type of OA and defined as OA showing a distinctive decrease in subchondral bone density accompanied by high remodeling rates. Further studies are needed to establish the relationship between bone fragility and knee OA at any phase.

### Table 4. Correlation coefficients among biomarkers of female hormones, bone metabolism, and inflammation. Spearman’s correlation coefficients were calculated. Only statistically significant correlations \((p < 0.05)\) were shown in this table.

| BMD  | AMH  | E2   | LH   | FSH  | Prolactin | Testosterone |
|------|------|------|------|------|-----------|--------------|
| AMH  | 0.491| −0.458| −0.555| 0.595| 0.185     | 0.127        |
| BMD  | 0.491| 0.496| −0.224| −0.334| 0.186     | 0.102        |
| Total PINP | −0.243| −0.260| −0.298| 0.198| 0.206     | −0.119       |
| BAP  | −0.365| −0.356| −0.363| 0.243| 0.261     | −0.163       |
| NTx  | −0.284| −0.392| −0.384| 0.328| 0.331     |              |
| TRACP-5b | −0.465| −0.506| −0.479| 0.351| 0.410     | −0.211       |
| Pentosidine | −0.298| −0.280| −0.328| 0.136| 0.234     | −0.119       |
| Homocysteine | −0.214| −0.152| −0.175| 0.141| 0.175     |              |
| sHA  | −0.516| −0.443| −0.388| 0.216| 0.259     | −0.132       |
| MMP-3|              | 0.095|        | 0.132|           |              |
| Hs-CRP| −0.131|        |        |        |           |              |
| Adipokine | −0.219| −0.280| −0.208| 0.192| 0.259     |              |
| Leptin| 0.125| 0.162| −0.097| −0.160| 0.122     |              |
| IL-6 | −0.244| −0.155|          |        |           |              |

### Table 5. Related factors for radiographic knee osteoarthritis. Logistic regression analysis by backward stepwise selection method was performed, with the presence of early knee osteoarthritis or knee osteoarthritis as dependent variable, and body mass index, bone mineral density, bone metabolic markers, and inflammation markers as independent variables. Furthermore, model 1 and 2 included categorized anti-Mullerian hormone (AMH) reduction (pre-menopause with AMH ≥ 0.08, pre-menopause with AMH < 0.08, or post-menopause). Model 3 included post-menopausal period by 5 years after menopause.

|                          | Standard partial regression coefficient | p value | Odds ratio | 95% confidence interval |
|--------------------------|----------------------------------------|---------|------------|------------------------|
| **Model 1:** Risk for early knee OA in pre-menopausal females (Categorized AMH) | | | | |
| AMH reduction            | 1.71                                   | 0.035   | 5.55       | 1.13–27.23             |
| Total PINP               | −0.05                                  | 0.106   | 0.95       | 0.90–1.01              |
| Leptin                   | 0.12                                   | 0.015   | 1.13       | 1.02–1.25              |
| **Model 2:** Risk for radiographic knee OA in overall females (Categorized AMH) | | | | |
| Body mass index          | 0.16                                   | <0.001  | 1.18       | 1.10–1.26              |
| Bone mineral density     | −4.40                                  | 0.002   | 0.01       | 0.01–0.19              |
| Hyaluronic acid          | 0.02                                   | <0.001  | 1.02       | 1.01–1.02              |
| Total PINP               | −0.01                                  | 0.106   | 0.99       | 0.98–1.00              |
| AMH reduction            | 0.46                                   | 0.032   | 1.59       | 1.04–2.42              |
| **Model 3:** Risk for radiographic knee OA in overall females (Postmenopausal period by 5 years) | | | | |
| Body mass index          | 0.16                                   | <0.001  | 1.17       | 1.10–1.25              |
| Bone mineral density     | −2.70                                  | 0.086   | 0.07       | 0.01–1.47              |
| Hyaluronic acid          | 0.01                                   | <0.001  | 1.01       | 1.01–1.02              |
| Post-menopausal period   | 0.22                                   | 0.005   | 1.24       | 1.07–1.44              |

et al. revealed that symptomatic BMLs on MRI were related to bone fragility, including lower BMD and high turnover of bone metabolism in middle-aged females without radiographic abnormalities. Furthermore, others reported a pathogenic mechanism since excessive bone resorption takes place in the early phase of OA. Previous reports support our results that lower BMD and increased bone metabolism of middle-aged females were correlated with the presence of knee OA. Indeed, osteoporotic osteoarthritis is reported as a particular type of OA and defined as OA showing a distinctive decrease in subchondral bone density accompanied by high remodeling rates. Further studies are needed to establish the relationship between bone fragility and knee OA at any phase.

Another interesting result in this study was that serum AMH concentration in the female population having knee OA was associated with serum inflammation markers. Systemic and focal inflammation in the synovium play an important role even in the early phase of knee OA. Inflammation is generally induced by microfragments of cartilages or danger-associated molecular pattern (DAMPs) in synovial fluids and releases several proteases and cytokines, which accelerate the degeneration of articular tissues. The infrapatellar fat pad is a major source of adiponectin in synovial fluid; adiponectins are closely related to the metabolic syndrome and degenerative pathological changes in the cartilage and bone during OA. In this study, the presence of early and
radiographic knee OA correlated with an increasing serum hyaluronan concentration. Previous reports indicated that the serum levels of hyaluronan is considered as a biomarker for synovitis, which reflects the severity of knee OA and degree of pain\textsuperscript{14,24}; additionally, this predicts future joint space narrowing over 5 years\textsuperscript{42}. AMH was a valuable and predictive biomarker for early knee OA, which indicated bone fragility and inflammation. However, the utility and reliability of systemic biomarkers in OA diagnosis was not validated; further studies are needed.

This study had several limitations besides the selection bias focusing only on middle- to old-aged females. First, the study sample was the general Japanese population; their background information and confounding factors were not completely evaluated. Second, the imaging examination was limited to the radiographs. Although the MRI and ultrasonographic imaging detected minute structural changes and inflammation of the knee joint\textsuperscript{21,31} especially in early knee OA, we could not use these modalities. However, by measuring many inflammation biomarkers, we could evaluate the minute changes of osteoarthritis. Furthermore, regarding radiographic examination, patellofemoral joint OA was not fully examined. Although crepitus was evaluated as one of the symptoms of patellofemoral OA, an imaging analysis was not performed. Imaging of patellofemoral joints could not be performed as a result of time constraints. However, patellofemoral OA should be assessed because of its significant effect on ADL and QOL\textsuperscript{46,47}. Third, BMD was measured only in the distal radius. Although it was ideal to evaluate the BMD of knee joint, it needs wide space and shield. In considering radiation exposure, it was difficult to measure the BMD of knee joint in the large sample cohort study. Finally, this cross-sectional cohort study could not conclude the causation between incidence of knee OA and reduced serum levels of AMH. Previously it is known that ovarian aging induces decreased female hormones, which affects the chondrocyte and subchondral bones. However, this has to be investigated by the longitudinal cohort study. Thus, a longitudinal observation was conducted in our cohort to estimate the real incidence of knee OA after AMH reduction and to validate its predictive values. Despite these limitations, this cohort study revealed the association of AMH and early knee OA during menopausal transition, in addition to the relationship between menopause and knee OA with lower BMD in middle-aged females. In considering the etiology of OA, Because serum levels of AMH decrease three years before menopause, which might reflect on knee OA via increasing bone metabolism, lower BMD, synovitis, or decreasing female hormones. Further longitudinal cohort study is needed.

In conclusion
Reduced serum levels of AMH were correlated with the presence of early knee OA. AMH might be one of the biomarker for early knee OA. Also the AMH were correlated with the higher bone metabolic markers, lower bone mineral density, higher synovitis markers.

Data availability
All of data and material are available from the database of Department of Orthopaedic Surgery and Social Medicine, Hiroasaki University Graduate School of Medicine.

Received: 2 December 2020; Accepted: 18 February 2021
Published online: 02 March 2021

References
1. Lawrence, R. C. et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41(5), 778–799 (1998).
2. Yoshimura, N. et al. Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J. Bone Miner. Metab. 27, 620–628 (2009).
3. Hiligsmann, M. et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin. Arthritis Rheum. 43(3), 303–313 (2013).
4. Luyten, F. P. et al. Lohmander LS toward classification criteria for early osteoarthritis of the knee. Semin. Arthritis Rheum. 47(4), 457–463 (2018).
5. Sasaki, E. et al. Early knee osteoarthritis prevalence is highest among middle-aged adult females with obesity based on new set of diagnostic criteria from a large sample cohort study in the Japanese general population. Knee Surg. Sports Traumatol. Arthrosoc. 28(3), 984–994 (2020).
6. Silverwood, V. et al. Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis. Osteoarthr. Cartil. 23(4), 507–515 (2015).
7. Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 339(10182), 1745–1759 (2019).
8. Muraki, S. et al. Prevalence of radiographic knee osteoarthritis and its association with knee pain in the elderly of Japanese population-based cohorts: the ROAD study. Osteoarthr. Cartil. 17(9), 1137–1143 (2009).
9. Omori, G. et al. Association of mechanical factors with medial knee osteoarthritis: a cross-sectional study from Matsudai Knee Osteoarthritis Survey. J. Orthop. Sci. 21(4), 463–468 (2016).
10. Kellgren, J. H. & Lawrence, J. S. Osteo-arthritis and disk degeneration in an urban population. Ann. Rheum. Dis. 17(4), 388–397 (1958).
11. Felson, D. T. The epidemiology of knee osteoarthritis: results from the Framingham Osteoarthritis Study. Semin. Arthritis Rheum. 20(3 Suppl 1), 42–50 (1990).
12. Zhang, Y. et al. Felson DT comparison of the prevalence of knee osteoarthritis between the elderly Chinese population in Beijing and whites in the United States: the Beijing osteoarthritis study. Arthritis Rheum. 44(9), 2065–2071 (2001).
13. Hanna, F. S., Teichtahl, A. J., Wluka, A. E., Wang, Y., Urquhart, D. M., English, D. R., Giles, G. G. & Cicuttini, F. M. Women have increased rates of cartilage loss and progression of cartilage defects in the knee than men: a gender study of adults without clinical knee osteoarthritis. Menopause 16(4), 666–670 (2009).
14. Black, D. M. & Rosen, C. J. Postmenopausal osteoporosis. N. Engl. J. Med. 374(21), 2096–2097 (2016).
15. Xu, X. et al. Estrogen modulates cartilage and subchondral bone remodeling in an ovariectomized rat model of postmenopausal osteoarthritis. Med. Sci. Monit. 29(25), 3146–3153 (2019).
16. Richette, P., Corvil, M. & Bardin, T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine. 70(4), 257–262 (2003).
17. Sherman, S. Defining the menopausal transition. Ann. J. Med. 19(118 Suppl 12B), 3–7 (2005).
Acknowledgements
We would like to thank the all of stuffs helping us for conducting Iwaki Health Promotion Project, and Editage (www.editage.jp) for English language editing.

Author contributions
E.S., D.C., and M.O. contributed to the conception and design of the study. E.S., S.O., M.O., K.I., and M.A. contributed to the acquisition of the data. E.S., D.C., S.O., Y.K., S.S., M.O., and Y.Y. contributed to the analysis and/or interpretation of the data. E.S., S.O., D.C. and M.O. drafted the manuscript. Y.Y., E.T., and Y.I. revised the manuscript critically for important intellectual content. D.C., S.O., Y.K., S.S., Y.Y., M.O., K.I., M.A., E.T., and Y.I. approved the final version of the manuscript to be published. Y.I. is the guarantor. The corresponding author attests that all listed authors meet the authorship criteria and that no other authors meeting the criteria have been omitted.

Funding
This study was supported in part by JST COI Grant Number JPMJCE1302, a Grant-in-Aid from the Japanese Society for the Promotion of Science (Nos. 21500676, 18K16606, 18K09091), Health Labor Sciences Research
Grant, JOA-Subsidized Science Project Research from the Japanese Orthopedic Association, and Grant of Japan Orthopaedics and Traumatology Research Foundation (No. 421).

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to E.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021